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A study was performed to compare, in a randomized way, the effect of pulsatile intravenous (iv) 
and intramuscular (im) human menopausal gonadotrophin (hMG) administration on hormonal 
serum profiles and follicular development in in vitro fertilization (IVF), Fourteen IVF patients 
participated in the study, aged between 20 and 40 years, with a normal endocrine profile, no 
hormonal medication used for at least 3 months previously, no endometriosis, both ovaries present 
and a normal male factor. Seven patients were treated with im hMG at a daily dose of 150IU and 
seven patients with pulsatile iv hMG at a daily dose of 112.5 IU, in both cases in combination with 
buserelin. Ultrasonography was performed every other day during the stimulation phase and blood 
samples were collected once daily up to five times a day during the entire IVF cycle. Serum 
concentrations of follicle-stimulating hormone, luteinizing hormone, 17/?-oestradiol, progesterone 
and human chorionic gonadotrophin were determined. There were no differences in hormonal 
profiles between the two groups. The numbers of retrieved oocytes, fertilization rates and mean 
embryo quality were identical in this study, as was follicular growth. In conclusion, in the present 
randomized study no differences were observed in hormonal levels or follicular development after 
im and pulsatile iv hMG treatment,
Ingrid JM Duijkers, Department of Obstetrics and Gynaecology, University Nijmegen St Radboud, PO Box 
9 1 0 1 , 6 5 0 0  HB Nijmegen, The Netherlands
Human menopausal gonadotrophin (hMG) has been 
used for almost 30 years to stimulate ovarian follicular 
growth. Urine-derived hMG preparations comprise 
follicle-stimulating hormone (FSH), luteinizing hor­
mone (LH) and human chorionic gonadotrophin 
(hCG), and are usually administered once daily by 
intramuscular (im) injection. The first reports on 
pulsatile intravenous (iv) administration of hMG were 
by Afnan et al. (1) and Ho Yuen et al. (2). By this route 
of administration, pulsatile gonadotrophin release by 
the pituitary gland is mimicked more closely than when 
the im route is used. Later, other authors compared im 
and pulsatile iv administration of hMG in ovulation 
induction cycles in women with refractory anovulation 
(3) and in in vitro fertilization (IVF) cycles, in low- 
responder patients and women with normal ovarian 
function (4, 5). Prak et al. (5) reported higher 
pregnancy rates after pulsatile iv than after im hMG 
treatment. However, as with all the investigations 
mentioned, their study did not have a randomized 
design, meaning that the higher pregnancy rates could
4
have been due to pre-existing differences between the 
study groups.
We decided to perform a randomized study to 
investigate whether the previously reported superior 
results obtained with pulsatile iv hMG treatment as 
against routine im treatment could be confirmed. The 
study was carried out in a well-defined group of women 
undergoing IVF treatment who had normal endocrine 
profiles. Administration of hMG was combined with 
gonadotrophin-releasing hormone agonist (GnRHa) 
treatment. We evaluated the effects of im and pulsatile 
iv hMG treatment on hormonal profiles in serum and on 
follicular development. Both hormonal profiles and 
follicular growth were monitored very closely to detect 
any differences between the two methods that might 
explain the possible increase in pregnancy rates. During 
the initial treatment days, multiple samples were taken 
to compare the increase of FSH and 17/3-oestradiol (E2) 
concentrations. In addition, the numbers of retrieved 
oocytes, fertilization rates and mean embryo quality 
were assessed in both groups.
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Subjects and methods 
Patients
Fourteen women undergoing IVF treatment for tubal 
pathology or unexplained infertility participated in the 
present study. The inclusion criteria were: age between 
20 and 40 years, normal endocrine serum profile in the 
early follicular phase of the cycle (FSH concentration 
< 8IU/1, LH/FSH ratio < 3, testosterone concentration 
<2 .5  nmol/1, prolactin concentration < 700 mIU/I and 
thyroxine concentration between 58 and 148 nmol/1), 
no hormonal medication for at least 3 months prior to 
the study, no endometriosis observed on laparoscopy, 
both ovaries present and a normal male factor (a 
normal semen analysis, i.e. at least 50% motile sperm, 
motility grade at least fairly good (i.e. score 4 on a scale 
from 1 to 6), at least 60% morphologically normal 
sperm and absence of antisperm antibodies as confirmed 
by the direct immunobead test (6); or a fertilization rate 
of at least 50% if the patient had IVF before).
The study was approved by the hospital's Ethical 
Committee and all the women gave their informed 
consent. The patients were allocated randomly to one of 
two groups. Seven patients received hMG (Humegon®, 
NV Organon, Oss, The Netherlands) via the im route 
(Group A), and the other seven patients received hMG 
via the pulsatile iv route (Group B).
The indication for IVF in Group A was tubal infertility 
in three patients and unexplained infertility in four 
patients. Two patients had had IVF treatment pre­
viously. In Group B the indication for IVF was also tubal 
infertility in three patients and unexplained infertility in 
four patients. Three patients had had IVF treatment 
previously. The groups were comparable with respect to 
mean age, weight and early follicular FSH concentra­
tions (33 years, 66 kg and 5.6 IU/I in Group A; 30 years, 
61kg and 7.2IU/1 in Group B).
Induction protocol
Intranasal administration of the GnRHa buserelin 
(Suprefact®, Hoechst AG, Frankfurt, Germany) was 
started on day 21 of the menstrual cycle, at a dose of 
300 /ig three times a day. On the tenth day of buserelin 
administration, transvaginal ultrasonography was 
performed to exclude the presence of ovarian cysts. 
Serum E2 concentration was determined the same day 
by time-resolved fluoroimmunoassay (Delfia, Wallac 
Oy, Turku, Finland). If the serum E2 concentration was 
below 500pmol/lf administration of hMG was started 
the next day (day 3 of the IVF cycle) and the buserelin 
medication was continued. If the E2 level remained 
higher than 500 pmol/1, the administration of buserelin 
was continued but hMG administration was postponed 
until the serum E2 concentration had fallen below 
500pmol/1 (determined every 2 or 3 days).
Humegon® was given either by im administration
between 17.00 and 18.00 h at a fixed dose ol two 
ampoules (150IU) daily, or by pulsatile iv administra­
tion at a fixed total daily dose of 1.5 ampoules 
(112.5 IU) with a pulse interval of 90min, The lower 
daily dose for the iv route as compared with the im route 
was based on the work ol Ho Yuen et al (2). who had 
described an approximately 40% reduction in the dose. 
We reduced the daily dose for the iv route to 1.5 
ampoules of hMG per day. An iv catheter was inserted 
into a forearm or upper arm vein. Six ampoules of hMG 
were diluted in 2.6 ml of prednisolone-heparin solution 
and 40 /xl was administered in each pulse via a 
computerized pump (MiniMed^ Inlusion Pump 404- 
SP, Minimed Technologies, Sylmar, CA, USA; Microdose 
Pump MRS 5, Disetronic AC, Burgdorf, Germany). The 
pump was refilled with fresh hMG solution every 4 days. 
Eleven patients were treated with Humegon1*' from the 
same batch, while the other three patients were treated 
with Humegon® from another batch with similar RSI-1 
and LH in vivo bioactivity (85 IU of FSH and <S I Hi of 
LH, and 79 IU of FSH and 68 IU of LH, respectively). 
The administration of gonadotrophins was discon­
tinued as soon as at least three large follicles were 
present (diameter > 15  mm), one of which had a 
diameter of > 2 0 mm, and the Ei concentration was 
higher than 1000 pmol/1 per large follicle. On the day 
these criteria were satisfied no hMG was administered 
im and the infusion pump for iv hMG administration 
was stopped immediately before the im hCG injection of 
10 000IU of hCG (Pregnyru\  NV Organon, Oss. The 
Netherlands) at 23.00 or 24.00 h. Buserelin was 
administered until 24.00 h that night,
Transvaginal ultrasound-guided oocyte retrieval was 
performed 35 h after the hCG injection. After oocyte 
retrieval, 5000 IU of hCG was injected im, followed by 
1500 IU ofhCG im between 10.00 and 12.00 h every 
other day until day 10 after follicle aspiration. Two 
batches ofhCG (5000IU and 1500 HI) were used for all 
patients. The retrieved oocytes were counted and their 
quality (immature, mature, postmature, luteinized) was 
scored. The number and quality of the embryos were 
scored also, on a scale from 1 (bad) to 5 (good). Hmbryo 
transfer was performed on day 3 after oocyte retrieval.
Blood sampling
Blood samples were collected between OH.00 and 
10.00h on days 20, 22, 24, 27 and 30 of the cycle 
prior to the IVF cycle (before and during buserelin 
treatment). If the hypo-oestrogenic state had not yet 
been reached, further samples were obtained every 2 or 
3 days hereafter until the serum E2 concentration was 
lower than 500 pmol/1. On the first day of hMG 
administration (day 3 of the IVF cycle) blood .samples 
were taken immediately before the first im injection (at 
17.00h) or before the insertion of the iv catheter 
(between 14.00 and 17.00 h), and also at 20.00 and 
23.00 h. The next day, blood samples were drawn at
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08.00, 12.00, 17.00, 20.00 and 23.00h. On day 5 
blood was collected at 08.00 and 17.00h. Thereafter, 
blood samples were taken once daily between 08.00 
and 10.00 h for the rest of the IVF cycle until the day of 
the pregnancy test or the first day of the next period. 
The blood was allowed to clot at room temperature; it 
was then centrifuged at 1000 g for 5 min and the serum 
samples were stored at - 2 0 UC until assayed.
Ultrasound
Vaginal ultrasound examinations were performed on 
day 20 of the previous cycle, on day 10 of buserelin 
administration and subsequently every other day from day
5 of the IVF cycle until the day of hCG administration.
Hormonal assays
Concentrations of FSH, LH and E? were determined in 
all serum samples. Progesterone concentrations were 
determined during the luteal phase of the previous 
cycle, i.e. the cycle before the actual treatment, on day 7 
of the stimulation phase and daily from day 12 of the 
stimulation phase onwards. Serum hCG concentrations 
were determined once daily during the treatment cycle. 
Concentrations or FSH and LH were determined by 
immunoradiometric assays that have been described 
previously (7). Concentrations of E2 and progesterone 
were determined by radioimmunoassays (8). Human 
chorionic gonadotrophin concentrations were measured 
by an immunoenxymetric assay specific for intact hCG 
(Tandem-E hCG, Hybritech Europe SA, Liège, Belgium).
Statistics
Concentrations below the detection limit were assigned 
the minimum detectable concentration for the assay.
Differences between the groups were evaluated using 
Wilcoxon’s rank sum test, in order to evaluate
hormonal profiles, a limited number of characteristics 
were selected, namely the increment in serum FSH and 
E2 concentrations in the stimulation phase, plateau FSH 
concentrations and peak E2 concentrations in the 
stimulation phase.
Results
The serum FSH, LH and E2 concentrations in the two 
groups are shown in Figs. 1, 2 and 3. One cycle in 
Group B was cancelled on cycle day 16 because of poor 
ovarian response. On ultrasonography no follicular 
growth was seen and serum E2 concentrations did not 
exceed 500 pmol/1. In another cycle in Group B none of 
the retrieved oocytes were fertilized, despite good semen 
motility. The results for the luteal phase of the previous 
cycle and for the stimulation phase in Figs. 1, 2 and 3 
include the values for the cancelled cycle and the cycle
without fertilization. The results for the luteal phase of 
the IVF cycle do not include the values of the said two 
cycles.
There were no significant differences between the 
groups treated by im and pulsatile iv hMG admini­
stration (Groups A and B, respectively). The rates of 
increase in serum FSH and E2 concentrations during the 
initial days of hMG administration were similar (see 
insets in Figs. 1 and 3). The plateau FSH concentration, 
defined as the mean concentration from day 5 to day 
10, was 8.9 IU/l in group A and 9.8 IU/lin Group B. The 
median values of the peak E2 concentrations on the day 
before oocyte retrieval were 17 000 pmol/1 in Group A 
and 15 500 pmol/1 in Group B.
Serum progesterone concentrations in the luteal 
phase of the previous cycle reached maximum values 
on day 24. The median value in Group A was 78 nmol/1 
(tenth percentile (p10) = 53 nmol/1 and ninetienth 
percentile (py())=  110 nmol/1) and in Group B it 
was 58 nmol/1 (p10 =  3 6 nmol/1 and p90 — 110 nmol/ 
1). During the stimulation phase of the IVF cycle, 
progesterone concentrations were undetectably low, 
increasing just before or just after the hCG injection. 
During the luteal phase of the IVF cycle high 
progesterone concentrations were observed, reach­
ing maximum values 9 days after oocyte retrieval. 
The maximum progesterone concentration in the non­
pregnant patients in Group A was 450 nmol/1 (median 
value; p1() — 2 3 0 nmol/1, p90 =  710nmol/1) and in 
Group B it was 580nmol/l (p1() =  490 nmol/1, 
pg() =  .1600 nmol/1). There were no significant differ­
ences between the groups.
The administration of hMG, which contained a 
certain amount of hCG, hardly influenced serum hCG 
levels. In the follicular phase of the IVF cycle serum hCG 
concentrations remained below the detection limit of 
the assay (2.5 IU/I), only increasing slightly on the last 
day before hCG administration (median value of 2.5 IU/l 
in Group A and 3 IU/l in Group B). One patient in Group 
B had raised hCG levels throughout the follicular phase 
(3.7-8.4 IU/l), even before the start of hMG adminis­
tration. When other assays for hCG were applied for 
these serum samples (another sandwich assay and a 
radioimmunoassay), hCG concentrations were below 
the detection limit of the assay (2.0 IU/l and 1.0 ng/ml, 
respectively). The increased hCG values, therefore, will 
not be of clinical relevance. After the administration of 
10 000IU of hCG, serum hCG levels increased. The 
maximum serum hCG concentration was reached on 
the first day after oocyte retrieval (the median value in 
Group A was 320 IU/I (pln =  150 IU/l, p90 =  460 IU/l) 
and in Group B it was 390 IU/l (pI() — 2 7 0 IU/l, 
p9()670IU/l)). Thereafter, a gradual fall in hCG 
concentrations was observed.
The median duration of the stimulation phase seemed 
shorter for Group B than for Group A (Table 1), but the 
difference was not statistically significant. The total 
number of ampoules used was lower for Group B than
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Fig, 2. Median serum follicle-stimulating hormone (FSH) concentrations (10th and 90th percentiles) during in vitro fertilization cycles in seven 
patients treated with human menopausal gonadotrophin (hMG) im (A) and seven patients treated with pulsatile iv hMG (B). From day h to the 
day of oocyte retreival (P) Group B comprised six patients, and during the luteal phase it comprised five patients. FSH anicwurations during the 
initial days of hMG treatment, when blood sampling was performed more frequently, are shown in the inset.
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Flfj. 2. Median serum luteinizing hormone (LH) concentrations (10th and 90th percentiles) during in vitro fertilization cycles in seven patients 
treated with human menopausal gonadotrophin (hMG) im (A) and seven patients treated with pulsatile iv hMG (B). From day 6 to the day of 
oocyte retrieval (P) Group B comprised six patients, and during the luteal phase it comprised five patients.
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Table 1. Cycle characteristics of seven patients treated with im human 
menopausal gonadotrophin (hMG) and seven patients treated with 
pulsatile iv hMG—median values with 10th and 90th percentiles in 
parentheses
hMG im hMG iv
Days of stimulation 12 (7-18) 9 (9-17)
Number of large follicles“ 12 (5-24) 12 (0-22)
Number of retrieved oocytes 11 (2-17) 12 (7-17)
Fertilization rate (%)h 76 (50-100) 76 (0-94)
Mean embryo quality1’ 3.9 (3.0-5.0) 3.5 (2.4 4.4)
1 Largest diameter >  15 mm, as measured at the last ultrasound 
examination. 
b Six patients in the group treated with hMG iv.
L’Seale 1 (bad) to 5 (good); live patients in the group treated with 
hMG iv.
for Group A (105 ampoules versus 158 ampoules) 
owing to the lower daily dose. Table 1 shows median 
values of the numbers of follicles with a diameter 
greater than 1 5 mm at the last ultrasonography before 
oocyte retrieval, the numbers of retrieved oocytes, the 
fertilization rates and the mean embryo quality in the 
two groups. There were no significant differences 
between the groups.
One patient in Group B experienced leakage from 
the infusion pump system on day 13 of the stimula­
tion phase of the cycle, leading to a drop in serum 
FSH concentrations from 12 to 4.9 IU/L This problem 
was corrected within 24 h and serum FSH concentra­
tions then increased again. Serum E2 concentrations 
did not decrease during this leakage problem. None of 
the patients showed signs of phlebitis. Three patients 
in Group A had a positive pregnancy test. One of the 
three had bleeding 2 days later and a second 
pregnancy test was negative. There were no pregnan­
cies in Group B.
Discussion
Hormonal profiles in the serum of women undergoing 
1VF treatment were monitored meticulously in th
present study. A large interindividual variation in 
hormonal concentrations was observed, but median 
values in the two groups did not show significant 
differences. The increase in FSH concentrations after the 
start of hMG treatment was comparable in the two 
groups, as was the plateau FSH level between days 5 
and 10 of the stimulation phase. In addition, the 
increase in E2 concentrations during hMG administra­
tion and the peak E2 concentrations were similar in the 
two groups. There were no differences between the 
groups as regards follicular growth, numbers of oocytes, 
fertilization rates or embryo quality. This indicates that 
pulsatile iv hMG administration does not lead to better 
results than the routine im hMG treatment.
It could be argued that the absence of better results
after pulsatile iv treatment was due to the lower daily 
dose in this group. This lower dose was based on the 
results of a previous study (2). However, the plateau 
FSH levels during hMG treatment were similar in the 
two groups, which means that the bioavailability of two 
ampoules of hMG administered im is comparable to that 
of 1.5 ampoules administered iv.
Previous studies on pulsatile iv hMG treatment 
showed that the pulsatile iv administration route was 
possibly more beneficial. Moreover, in one of these 
studies a lower daily hMG dose was used for pulsatile iv 
treatment as compared with im treatment. The first 
reports of the successful induction of ovulation by 
pulsatile iv hMG administration were by Afnan et al. (1) 
and Ho Yuen et al. (2). Ho Yuen and co-workers (3) 
reported the results of 107 pulsatile iv hMG treatment 
cycles in 30 women with refractory anovulation. 
Twelve women with polycystic ovary (PCO) syndrome 
had had previous im treatment cycles. Retrospective 
comparison of the two treatment methods reveals that 
less hMG was needed in the iv treatment cycles than in 
the im treatment cycles.
Edelstein et al, (4) performed a study involving six IVF 
patients with a low response to high-dose gonadotro­
phin administration (450IU of purified FSH daily). They 
were treated with 450 IU of FSH per day by pulsatile iv 
administration. Although the plateau FSH levels were 
significantly higher after iv than after im treatment, the 
numbers of oocytes and fertilization rates did not 
improve after iv treatment. The authors concluded 
that pulsatile iv gonadotrophin treatment was not of 
major benefit for the stimulation of low-responder 
patients,
Prak et al. (5) gave hMG by pulsatile iv administra­
tion over 82 IVF cycles in women with tubal or 
unexplained infertility, They compared the results 
with those for 231 cycles in which hMG was 
administered im. The hMG therapy was combined 
with GnRHa treatment. The dose of hMG was 40% 
lower than that used in a previous cycle of im 
treatment. The numbers of follicles and oocytes were 
similar in the two groups but the pregnancy rate was 
significantly higher in the group treated iv than in the 
im treatment group. The authors ascribed this higher 
pregnancy rate to improved oocyte quality and 
endometrial receptivity as a result of the more 
physiological method of ovarian stimulation. How­
ever, none of the previously published studies was 
well-controlled and randomized.
As stated above, the fact that the beneficial effect of 
pulsatile iv hMG administration could not be confirmed 
in a randomized trial indicates that differences between 
study groups in previous investigations may explain 
the results. However, further randomized studies are 
needed in patients suffering from PCO syndrome and 
patients whose response was poor in previous cycles.
The half-life of FSH, as present in hMG, is approxi­
mately 11 h after iv administration (9). Because of the
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long half-life, pulsatile hMG administration will result in 
a gradual accumulation of FSH in the circulation, 
instead of a pulsatile FSH pattern. In contrast to the 
pulsatile iv GnRH treatment, where because of the very 
short half-life of GnRH a clear pulsatile pattern is 
present (10), the individual hMG pulses will contribute 
very little to the high plateau FSH level. This is 
supported by our results during the initial treatment 
days, showing a gradual increase in FSH concentrations 
leading to a steady-state level, with comparable patterns 
in the two groups. To investigate whether very small 
fluctuations in the plateau FSH level occur during 
pulsatile iv treatment, very frequent blood sampling is 
required. The long half-life of FSH and the similar 
patterns of serum FSH concentrations during the entire 
stimulation period explain why pulsatile iv hMG 
treatment did not lead to better results.
In conclusion, the results of the present study indicate 
that the effect of pulsatile iv hMG treatment is not 
superior to that of im treatment in women with normal 
endocrine profiles. Moreover, the pulsatile iv treatment 
has practical disadvantages as compared with im 
treatment, namely the vulnerability of the administra­
tion system, as illustrated by the leakage from the 
infusion system experienced by one of the patients. 
Inserting and refilling the infusion system are time- 
consuming procedures. Furthermore, there is the 
serious risk of flebitis and subsequent sepsis, complica­
tions that were seen during pulsatile iv GnRH 
treatment. The routine im hMG treatment remains, 
therefore, preferable to pulsatile iv treatment.
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